AI assistant
Bonesupport Holding — Regulatory Filings 2020
Dec 17, 2020
3016_rns_2020-12-17_92cba523-fa3e-4f84-b5e3-9d27c3a26c4c.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
Press Release
BONESUPPORT moves to Mid Cap
Lund, Sweden, 11.00 CET, Dec 17, 2020 BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, will be moved to the Mid Cap segment on Nasdaq Stockholm from 4 January 2021.
Based on Nasdaq Nordic's recent annual review of the market capitalization segments, BONESUPPORT AB will be moved from the Small Cap to the Mid Cap segment.
For more information contact:
BONESUPPORT AB Emil Billbäck, CEO +46 (0) 46 286 53 70
Håkan Johansson, CFO +46 (0) 46 286 53 70 [email protected]
Cord Communications
Charlotte Stjerngren +46 (0) 708 76 87 87 [email protected] www.cordcom.se
About BONESUPPORT™
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits that its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 155 million in 2019. Please visit http://www.bonesupport.comfor more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.